Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function

作者：Raghavan R P^*; Laight D W; Cummings M H

来源：International Journal of Clinical Practice, 2014, 68(2): 271-277.

DOI：10.1111/ijcp.12310

ObjectivesThe effect of aspirin upon platelet function is well documented although experimental studies suggest that aspirin may also affect oxidative stress, vascular inflammation, endothelial dysfunction and dysglycaemia. The optimal dose of aspirin for cardiovascular protection in type 2 diabetes is still debated. We examined the effects of different doses of aspirin upon these novel markers of cardiovascular risk and any association between aspirin-mediated changes in these markers. %26lt;br%26gt;MethodologySubjects with type 2 diabetes attended for baseline evaluation including BMI, glycaemic and lipid markers, endothelial photoplethysmography), insulin resistance (HOMA), inflammation (sVCAM-1 and Hs-CRP) and markers of oxidative stress [total anti-oxidant status (TAOS and FRAP), whole blood total glutathione (GSH) assays]. Subjects then received in random, sequential, blinded fashion aspirin 75mgday(-1), aspirin 300mgday(-1), aspirin 3.6gday(-1) or placebo for 2 weeks with a 2-week washout. The above investigations were repeated after each intervention. Aspirin-related changes compared with placebo were analysed using repeated measures ANOVA. %26lt;br%26gt;ResultsSubjects=17 (M - 12; F - 5), mean age - 57.49.1years (mean +/- 1 SD), HbA1c - 63 +/- 13mmolmol(-1) (7.9 +/- 1.2%), total cholesterol 4.57 +/- 1.01mmoll(-1). At baseline TAOS value was 59.3 +/- 9.7M AEAC (Ascorbate Equivalent Anti-oxidant Concentration), glutathione 302.2 +/- 183.3mmoll(-1) and FRAP 0.86 +/- 0.23mM FeII. None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP). %26lt;br%26gt;ConclusionsAspirin exhibited no significant dose-dependent effect on markers of vascular inflammation, oxidative stress, insulin resistance and endothelial photoplethysmography) when used in type 2 diabetes over a 2-week period. (Clinical trials registration: NCT00898950, EUDRACT:2004-001418-14)

• 出版日期2014-2